

XEDAR Antibody

XEDAR: X-linked ectodysplasin-A2 receptor, EDA-A2 receptor, TNFRSF27

CATALOG NO.: 3855

BACKGROUND:

X-linked ectodysplasin-A2 receptor (XEDAR) is a recently isolated member of the tumor necrosis factor receptor family that is highly expressed during embryonic development and binds to ectodysplatin-A2 (EDA-A2) (1). Two predominantly expressed isoforms, XEDAR-s and XEDAR-L, differ by only a 21-amino region at the juxtamembrane region of the cytoplasmic domain. Neither isoform possesses a death domain and both have been shown to act mainly through TRAF3 and TRAF6 to activate the NF- κ B and JNK pathways (2). Cells transfected with XEDAR and treated with EDA-A2 cause the assembly of a secondary complex containing FADD, caspase-8 and caspase-10, leading to the activation caspase-8 and caspase-3, and finally apoptosis (3). The EDA-A2-induced apoptosis is dependent on caspase-9 activation, as various pharmacological and genetic inhibitors of caspase-8 blocked apoptosis following EDA-A2 treatment (3).

SOURCE:


Rabbit polyclonal XEDAR antibody was raised against recombinant human XEDAR (Genbank accession No. AAQ89953).

APPLICATION:

XEDAR antibody can be used for the detection of XEDAR by Western blot at 0.5 – 1 μ g/ml. (Optimal dilution should be determined by user.) 293 cell lysate can be used as positive control. XEDAR antibody is human specific. **This product is for research use only.**

STORAGE:

XEDAR antibody is supplied as immunoaffinity purified IgG in PBS containing 0.02% sodium azide. Store at 4°C, stable for one year.



Western blot analysis of XEDAR in 293 cell lysate with XEDAR antibody at (A) 0.5, (B) 1 and (C) 2 μ g/ml.

RELATED PRODUCTS:

293 Cell Lysate, Catalog No. **1210**.
TRAF3 Antibody (NT), Catalog No. **3601**.
TRAF6 Antibody, Catalog No. **3129**.
Caspase-8 Antibody (IN), Catalog No. **3475**.

REFERENCES:

1. Yan M, Wang LC, Hymowitz SG, et al. Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors. *Science* 2000; 290:523-7.
2. Sinha SK, Zachariah S, Quinones HI, et al. Role of TRAF3 and -6 in the activation of the NF-kappaB and JNK pathways by X-linked ectodermal dysplasia receptor. *J. Biol. Chem.* 2002; 277:44953-61.
3. Sinha SK and Chaudhary PM. Induction of apoptosis by X-linked ectodermal dysplasia receptor via a caspase 8-dependent mechanism. *J. Biol. Chem.* 2004; 41873-81.
(WD0206)